technologiesTechnologyEmerging

Proteomics & phosphoproteomics

Measuring the proteins in a tumour, which is what drugs actually hit, rather than the genes that encode them.

Mass-spectrometry proteomics (CPTAC) reveals pathway activity and ADC target abundance that transcript levels do not predict. Quantitative IHC and mass-spec assays of HER2 and TROP2 aim to improve ADC patient selection.

Schematic · not to scale

Peptide peaks (mass spec) · m/z

How it works

Liquid chromatography tandem mass spectrometry with isobaric labelling quantifies proteins and phosphosites.

Strengths

Direct measurement of drug targets and signalling

Limitations

Throughput and standardisation

Latest papers

Literature trend4,357 papers in the last 12 months+13% vs prior 12How this is computed

Latest papers · live from Europe PMC

Open in Europe PMC

Query for this technology: (TITLE:"proteomics" OR ABSTRACT:"proteomics" OR TITLE:"proteogenomic" OR ABSTRACT:"proteogenomic" OR TITLE:"phosphoproteomics" OR ABSTRACT:"phosphoproteomics") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Proteomics & phosphoproteomics, not a curated reading list.

Connected

fronts

2

Diagnostics & Biomarkers Drug Discovery Platforms

technologies

2

Proteomics instruments and affinity platforms Spatial-omics-guided treatment selection

companies

2

Bruker (Bruker Spatial Biology)Elucidate Bio

institutions

4

EMBL's European Bioinformatics Institute Frederick National Laboratory for Cancer Research Uppsala University Hospital / Uppsala University Weizmann Institute of Science

terms

1

roadmaps

1

Early detection roadmap: organ screening → blood tests for many cancers

ideas

12

A blood test for the pre-metastatic niche A commons for leftover trial biospecimens with standard access for approved research A global rapid tissue donation network for metastatic disease A public biomarker validation utility with pre-diagnostic biobanks and blinded testing An open map of which cancer proteins any drug can stick to Find E3 ligases that only tumours have, and build degraders around them Find the parts of a tumour the drug never reaches Keep a freshly removed tumour alive on a pump and test drugs in it Screen glue-like compounds against every cancer cell line and publish it Select cachexia trial patients by the hormone driving their wasting Shared splice-derived neoantigens as off-the-shelf vaccine targets Time immunotherapy to the moment targeted drugs make tumours visible

collections

2

CPTAC (Clinical Proteomic Tumor Analysis Consortium)Human Protein Atlas

people

3

Eric B. Haura Li Ding Yi-Zhou Jiang